Parametric response map as an imaging biomarker to distinguish progression from pseudoprogression in high-grade glioma

Journal of Clinical Oncology

Volumn 28, Issue 13, 2010, Pages 2293-2299

  Tsien, Christina ^a   Galbán, Craig J ^a   Chenevert, Thomas L ^a   Johnson, Timothy D ^a   Hamstra, Daniel A ^a   Sundgren, Pia C ^a   Junck, Larry ^a   Meyer, Charles R ^a   Rehemtulla, Alnawaz ^a   Lawrence, Theodore ^a   Ross, Brian D ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXYMETHYLCELLULOSE POLYCYTIDYLIC POLYINOSINIC ACID POLYLYSINE; GEMCITABINE; TEMOZOLOMIDE; CONTRAST MEDIUM; DIAGNOSTIC AGENT; GADOLINIUM PENTETATE;

ADULT; AGE; ARTICLE; BRAIN BLOOD FLOW; BRAIN BLOOD VOLUME; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CHEMORADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; GLIOMA; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; KARNOFSKY PERFORMANCE STATUS; MULTIPLE CYCLE TREATMENT; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RADIATION DOSE; TUMOR VOLUME; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; BIOPSY; BLOOD FLOW; BLOOD VOLUME; BRAIN CIRCULATION; BRAIN TUMOR; CANCER STAGING; CHI SQUARE DISTRIBUTION; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; HEMODYNAMICS; MIDDLE AGED; NEUROSURGERY; PATHOLOGY; PREDICTION AND FORECASTING; PROSPECTIVE STUDY; STATISTICAL MODEL; TIME; TREATMENT OUTCOME; VASCULARIZATION;

ADULT; BIOPSY; BLOOD VOLUME; BRAIN NEOPLASMS; CEREBROVASCULAR CIRCULATION; CHEMOTHERAPY, ADJUVANT; CHI-SQUARE DISTRIBUTION; CONTRAST MEDIA; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; GADOLINIUM DTPA; GLIOMA; HEMODYNAMICS; HUMANS; LIKELIHOOD FUNCTIONS; LOGISTIC MODELS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; NEOPLASM STAGING; NEUROSURGERY; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RADIATION DOSAGE; RADIOTHERAPY, ADJUVANT; REGIONAL BLOOD FLOW; TIME FACTORS; TREATMENT OUTCOME;

EID: 77952294120     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.25.3971     Document Type: Article

References (22)

1. Stupp R, Mason WP, van den Bent MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996, 2005 (Pubitemid 40349501)
2. Stupp R, Hegi ME, Mason WP, et al: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459-466, 2009
3. de Wit MC, de Bruin HG, Eijkenboom W, et al: Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression. Neurology 63:535-537, 2004 (Pubitemid 39031388)
4. Brandsma D, Stalphers L, Taal W, et al: Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 9:453-461, 2008 (Pubitemid 351597795)
5. Taal W, Brandsma D, de Bruin H, et al: Incidence of early pseudoprogression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer 113:405-410, 2008
6. Brandes AA, Franceschi E, Tosoni A, et al:MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 26:2192-2197, 2008
7. Gerstner ER, McNamara MB, Norden AD, et al: Effect of adding temozolomide to radiation therapy on the incidence of pseudoprogression. J Neurooncol 94:97-101, 2009
8. Cao Y, Sundgren PC, Tsien CI, et al: Physiologic and metabolic magnetic resonance imaging in gliomas. J Clin Oncol 24:1228-1235, 2006 (Pubitemid 46622025)
9. Cao Y, Tsien CI, Nagesh V, et al: Clinical investigation survival prediction in high-grade gliomas by MRI perfusion before and during early stage of RT. Int J Radiat Oncol Biol Phys 64:876-885, 2006 (Pubitemid 43183588)
10. Jensen RL: Brain tumor hypoxia: Tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target. J Neurooncol 92:317-335, 2009
11. Galbán CJ, Chenevert TL, Meyer CR: The parametric response map: An imaging biomarker for early cancer treatment outcome. Nat Med 15:572-576, 2009
12. Curran WJ, Scott C, Horton J, et al: Recursive portioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 85:704-710, 1993 (Pubitemid 23133591)
13. Macdonald DR, Cascino TL, Schold SC Jr, et al: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277-1280, 1990 (Pubitemid 20195640)
14. Meyer CR, Boes JL, Kim B, et al: Demonstration of accuracy and clinical versatility of mutual information for automatic multimodality image fusion using affine and thin-plate spline warped geometric deformations. Med Image Anal 1:195-206, 1997
15. Chen W, Delaloye S, Silverman DH, et al: Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: A pilot study. J Clin Oncol 25:4714-4721, 2007 (Pubitemid 350086472)
16. Chan AA, Lau A, Pirzkall A, et al: Proton magnetic resonance spectroscopy imaging in the evaluation of patients undergoing gamma knife surgery for grade IV glioma. J Neurosurg 101:467-475, 2004 (Pubitemid 39100724)
17. Law M, Young RJ, Babb JS, et al: Gliomas: Predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 247:490-498, 2008
18. Aronen HJ, Pardo FS, Kennedy DN, et al: High microvascular blood volume is associated with high glucose uptake and tumor angiogenesis in human gliomas. Clin Cancer Res 6:2189-2200, 2000 (Pubitemid 30399184)
19. Provenzale JM, Wang GR, Brenner T, et al: Comparison of permeability in high-grade and low-grade brain tumors using dynamic susceptibility contrast MR imaging. AJR Am J Roentgenol 178:711-716, 2002 (Pubitemid 34178155)
20. Clarke JL, Chang S: Pseudoprogression and pseudoresponse: Challenges in brain tumor imaging. Curr Neurol Neurosci Rep 9:241-246, 2009
21. Sorensen AG, Batchelor T, Wen Patrick Y: Response criteria for glioma. Nat Clin Pract Oncol 5:634-644, 2008
22. Chamberlain M, Glantz M, Chalmers L, et al: Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma. J Neurooncol 82:81-83, 2007